Xencor (XNCR) EBT (2013 - 2026)
Xencor (XNCR) posted quarterly EBT of -$128.6 million for Q1 2026, down 166.52% year-over-year from $193.4 million in Q1 2025, and down 2915.38% quarter-over-quarter from -$4.3 million in Q4 2025.
Analysis
Xencor (XNCR) EBT (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported EBT for 14 consecutive years, with -$128.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 166.52% year-over-year to -$128.6 million; the TTM figure through Mar 2026 stood at -$170.0 million (up 18.69% YoY), while the FY2025 annual figure was -$89.6 million, up 61.85% from the prior year.
- EBT retreated to -$128.6 million in Q1 2026 per XNCR's latest filing, from -$4.3 million in the prior quarter.
- Across five years, EBT topped out at $25.8 million in Q1 2022 and bottomed at -$128.6 million in Q1 2026.
- Historically, EBT has averaged -$41.1 million across 5 years, with a median of -$44.6 million in 2024.
- Annual changes were most pronounced in 2022 — EBT jumped 259.43% — and 2023, when it slumped 327.17%.
- Xencor's EBT stood at -$12.5 million in 2022, then retreated by 1.53% to -$12.6 million in 2023, then plunged by 252.49% to -$44.6 million in 2024, then soared by 90.43% to -$4.3 million in 2025, then slumped by 2915.38% to -$128.6 million in 2026.
- Business Quant data shows XNCR's EBT at -$128.6 million in Q1 2026, -$4.3 million in Q4 2025, and -$6.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 542.00 Mn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | -767.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 312.46 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Xencor | 2.01 Bn | 1.63 Bn | - | -21.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.92 Mn |
| Mar 31, 2026 | -128.64 Mn |
| Dec 31, 2025 | -4.27 Mn |
| Sep 30, 2025 | -6.03 Mn |
| Jun 30, 2025 | -31.08 Mn |
| Mar 31, 2025 | -48.27 Mn |
| Dec 31, 2024 | -44.58 Mn |
| Sep 30, 2024 | -47.44 Mn |
| Jun 30, 2024 | -68.78 Mn |
| Mar 31, 2024 | -74.12 Mn |
| Dec 31, 2023 | -12.65 Mn |
| Sep 30, 2023 | -24.27 Mn |
| Jun 30, 2023 | -26.00 Mn |
| Mar 31, 2023 | -57.85 Mn |
| Dec 31, 2022 | -12.46 Mn |
| Sep 30, 2022 | -31.67 Mn |
| Jun 30, 2022 | -28.00 Mn |
| Mar 31, 2022 | 26.47 Mn |
| Dec 31, 2021 | 73.06 Mn |
| Sep 30, 2021 | -40.19 Mn |